CD19 CAR T细胞治疗自身免疫病——一项随访病例系列
该病例系列评估15例严重系统性红斑狼疮(8例)、特发性炎性肌病(3例)或系统性硬化(4例)患者,经氟达拉滨和环磷酰胺预处理后接受单次CD19嵌合抗原受体(CAR)T细胞输注。中位随访15个月,所有狼疮患者达DORIS缓解,所有炎性肌病患者达ACR-EULAR主要临床缓解,所有硬皮病患者EUSTAR活动指数评分下降,免疫抑制治疗全部停用。
要点
- 15例严重自身免疫病患者接受单次CD19 CAR T细胞输注,中位随访15个月。
- 所有狼疮患者达DORIS缓解,所有炎性肌病患者达ACR-EULAR主要临床缓解。
- 所有硬皮病患者EUSTAR活动指数评分下降,免疫抑制治疗全部停用。
核心结论
- 在该病例系列中,CD19 CAR T细胞输注在三种不同自身免疫病中似乎可行、安全且有效,为进一步对照临床试验提供了依据。
研究设计与样本
- 病例系列评估15例严重系统性红斑狼疮(8例)、特发性炎性肌病(3例)或系统性硬化(4例)患者,经氟达拉滨和环磷酰胺预处理后接受单次CD19 CAR T细胞输注。
- 疗效评估包括系统性红斑狼疮缓解定义(DORIS)缓解标准、美国风湿病学会-欧洲抗风湿病联盟(ACR-EULAR)主要临床缓解和欧洲硬皮病试验与研究组(EUSTAR)活动指数评分等,随访至CAR T细胞输注后2年。
- 记录细胞因子释放综合征和感染等安全性变量。
主要发现
- 中位随访15个月(范围4至29)。
- B细胞发育不全的平均(±标准差)持续时间为112±47天。
- 所有系统性红斑狼疮患者达DORIS缓解,所有特发性炎性肌病患者达ACR-EULAR主要临床缓解,所有系统性硬化患者EUSTAR活动指数评分下降。
- 所有患者免疫抑制治疗完全停用。
- 10例发生1级细胞因子释放综合征;各1例发生2级细胞因子释放综合征、1级免疫效应细胞相关神经毒性综合征和导致住院的肺炎。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment for autoimmune diseases such as systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis often involves long-term immune suppression. Resetting aberrant autoimmunity in these diseases through deep depletion of B cells is a potential strategy for achieving sustained drug-free remission. METHODS: We evaluated 15 patients with severe SLE (8 patients), idiopathic inflammatory myositis (3 patients), or systemic sclerosis (4 patients) who received a single infusion of CD19 chimeric antigen receptor (CAR) T cells after preconditioning with fludarabine and cyclophosphamide. Efficacy up to 2 years after CAR T-cell infusion was assessed by means of Definition of Remission in SLE (DORIS) remission criteria, American College of Rheumatology-European League against Rheumatism (ACR-EULAR) major clinical response, and the score on the European Scleroderma Trials and Research Group (EUSTAR) activity index (with higher scores indicating greater disease activity), among others. Safety variables, including cytokine release syndrome and infections, were recorded. RESULTS: The median follow-up was 15 months (range, 4 to 29). The mean (±SD) duration of B-cell aplasia was 112±47 days. All the patients with SLE had DORIS remission, all the patients with idiopathic inflammatory myositis had an ACR-EULAR major clinical response, and all the patients with systemic sclerosis had a decrease in the score on the EUSTAR activity index. Immunosuppressive therapy was completely stopped in all the patients. Grade 1 cytokine release syndrome occurred in 10 patients. One patient each had grade 2 cytokine release syndrome, grade 1 immune effector cell-associated neurotoxicity syndrome, and pneumonia that resulted in hospitalization. CONCLUSIONS: In this case series, CD19 CAR T-cell transfer appeared to be feasible, safe, and efficacious in three different autoimmune diseases, providing rationale for further controlled clinical trials. (Funded by Deutsche Forschungsgemeinschaft and others.).
引用
- Müller F, Taubmann J, Bucci L, et al. CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up. N Engl J Med. 2024. PMID: 38381673. doi:10.1056/NEJMoa2308917
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。